Welcome to our dedicated page for Becton Dickinson & news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & stock.
Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (Becton, Dickinson and Company) announced a peer-reviewed study in Obstetrics & Gynecology highlighting the effectiveness of molecular diagnostics in diagnosing vaginitis. The study found that clinician assessments missed 45.3% of positive cases and incorrectly identified 12.3% of negative cases. With vaginitis affecting 6 to 10 million women annually in the U.S., this study emphasizes the need for accurate diagnostic tools. The BD MAX™ Vaginal Panel Assay provides quicker and more accurate results, enhancing treatment decisions for patients.
The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.87 per common share. This dividend is scheduled for payment on March 31, 2022, to shareholders of record as of March 10, 2022. The indicated annual dividend rate stands at $3.48 per share, reflecting BD's commitment to returning value to its shareholders.
BD (Becton, Dickinson and Company) announced a significant advancement in flow cytometry through its new BD CellView™ Image Technology, highlighted in the journal Science. This technology allows for the sorting of individual cells at speeds of up to 15,000 cells per second, integrating fluorescence imaging for enhanced analysis. The system captures detailed images, enabling precise identification of biomarkers and their distributions, which could accelerate research in immunology and genomics. The technology promises to transform cell-based therapeutic discovery, filling long-standing gaps in biomedical research.
Summary not available.
BD (Becton, Dickinson and Company) announces a collaboration with Pfizer and Wellcome to enhance antimicrobial stewardship through improved diagnostic practices. This initiative aims to identify gaps in current diagnostic testing related to antimicrobial resistance (AMR), which poses a significant global health challenge, potentially leading to 10 million deaths annually by 2050. Experts emphasize the need for better diagnostic tools and education to combat AMR effectively. The COVID-19 pandemic has highlighted the importance of diagnostics in managing antibiotic use.
BD (Becton, Dickinson and Company) has received FDA 510(k) clearance for its BD Kiestra™ IdentifA system, aimed at automating microbiology bacterial identification testing. This automated system utilizes BD Synapsys™ informatics and robotics to enhance accuracy and efficiency, reducing human error in sample preparation. The BD Kiestra™ IdentifA is notable for being the only FDA-cleared solution integrated into a track-connected lab automation system. This innovation seeks to improve patient management by accelerating pathogen identification, thereby supporting better clinical decision-making.
BD (Becton, Dickinson and Company) has announced that its 2022 Annual Meeting of Shareholders will be held virtually on January 25, 2022, at 1:00 p.m. EST, due to health concerns related to the COVID-19 pandemic. Shareholders of record as of December 6, 2021, can participate in the meeting. Various registration options are available for both registered and street holders of shares. BD encourages shareholders to vote and submit proxies in advance.
BD (Becton, Dickinson and Company) has released its 2021 Cybersecurity Annual Report to inform stakeholders about health care cybersecurity challenges and trends. The report highlights key issues, including cybersecurity risks like phishing and ransomware, and emphasizes the need for collaboration in enhancing security measures across the industry. It introduces best practices for health care providers and outlines upcoming trends such as software-bill-of-materials (SBOM) requirements for 2022. BD aims to integrate cybersecurity throughout its product lifecycle for improved patient care.
BD (Becton, Dickinson and Company) (NYSE: BDX) will release its financial results for Q1 of fiscal year 2022 on February 3, 2022, at 6 a.m. ET. The announcement will include summary financial data for the quarter ending December 31, 2021. Following the release, management will host an audio webcast at 8 a.m. ET to discuss results and operational strategies. For further details and the live audio link, visit www.bd.com/investors. BD is committed to advancing healthcare through innovative technology and solutions.
BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent medical technology leader, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 2:15 p.m. Eastern Time. The presentation will be accessible via live webcast on BD's investor relations website, with a replay available afterward. BD focuses on advancing health through technology, diagnostics, and care delivery, supporting healthcare providers and enhancing patient outcomes globally.